{
  "id": 3110795,
  "title": "Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results",
  "url": "https://urgent.news/2026/08/24/bausch-lomb-advancing-two-first-in-class-eye-health-therapies-based",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T20:35:46.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/bausch-lomb-advancing-two-first-in-class-eye-health-therapies-based-on-trial-results"
  },
  "original_language": "en",
  "account": null,
  "summary": "Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1 VAUGHAN, Ontario — Bausch + Lomb Corporation […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}